Genetic Susceptibility to Tumor Recurrence and Progression in Patients With Non-Muscle Invasive Bladder Cancer

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Memorial Sloan-Kettering Cancer Center
ClinicalTrials.gov Identifier:
NCT00582387
First received: December 19, 2007
Last updated: July 11, 2013
Last verified: July 2013
  Purpose

The purpose of the study is to see if we will be more able to tell what the risk is for bladder cancer to reoccur or worsen when genetics and risk factors are examined along with the stage and grade of the tumor. Superficial bladder cancer is a cancer that does not grow into the muscle layer of the bladder wall. Even though it is a superficial cancer, this type of cancer tends to come back after being treated and is often more aggressive when it returns. We already know, that the "stage" or how deeply the tumor grows into the bladder wall and the "grade" or how fast the tumor grows affect whether the tumor will come back or get worse over time. Now we use information about the stage and grade of your tumor to decide how to treat the tumor and how often you should be checked after the treatment is over. However, this has not been very reliable, because each person has unique genetic characteristics and other factors that are likely to affect what happens to the tumor over time. For instance, we know the risk for developing a cancer may be affected by your surroundings and other factors such as what you eat, the type of habits you have such as smoking, and the type of job you have, but not everyone exposed to the same risk factors gets a cancer. We believe this is due to unique genetic characteristics in each person which may help their body fight cancer.


Condition Intervention
Bladder Cancer
Urinary Cancer
Nonmuscle Invasive Bladder Cancer
Genetic: Questionaire, specimen samples

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Prevention
Official Title: Pilot Study: Genetic Susceptibility to Tumor Recurrence and Progression in Patients With Non-Muscle Invasive Bladder Cancer

Resource links provided by NLM:


Further study details as provided by Memorial Sloan-Kettering Cancer Center:

Primary Outcome Measures:
  • Evaluate genetic variants (in the DNA repair genes, cell cycle genes, and detoxifying genes) and their association with recurrence and progression in early stage bladder cancer. [ Time Frame: conclusion of study ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Compare the DNA damage/repair capacity with the genetic variants. [ Time Frame: conclusion of study ] [ Designated as safety issue: No ]

Enrollment: 116
Study Start Date: March 2004
Study Completion Date: July 2013
Primary Completion Date: July 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1 nonmuscle invasive bladder cancer Genetic: Questionaire, specimen samples
baseline evaluation at MSKCC o You will be asked to fill out four surveys: A survey about your health A survey about how much and what (water, juice, liquor etc.) you drink A survey about what kind of food you eat A survey about smoking Blood will be collected. (Around 30cc)A Tissue sample will be collected during your biopsy. If a biopsy of the bladder is not planned by your doctor, then we will need to put a small tube into your bladder to take about 34 ounces of fluid.
Other Names:
  • After one year You will be asked to fill out three surveys:
  • A followup survey about your health A survey about how much and what (water, juice, liquor etc.) you
  • drink A survey about what kind of food you eat

Detailed Description:

This is a hospital based cohort study where subjects diagnosed within twelve months with nonmuscle invasive bladder cancer will be evaluated to determine whether candidate genetic variants are associated with the risk of recurrence and progression. Known tumor variables will be stratified and correlated with markers. The long term goal is to estimate the predicted risk of recurrence or progression well enough to modify surveillance schedules. Since 40% of superficial bladder cancer patients will never recur or progress, these individuals could return less frequently for followup, saving costs and discomfort. All patients will receive usual care and be followed to determine rates of recurrence and progression of the disease. Each subject will donate 30 ml of blood for extraction of genomic DNA and isolation of lymphocytes to assess DNA damage/repair function. In addition, each subject who undergoes a transurethral resection of the bladder (TURB) and/or random bladder biopsies as part of his/her usual care will donate urothelial cells from the random bladder biopsies for analyses of DNA damage/repair function. The DNA repair capacity of lymphocytes will be correlated with that of normal bladder tissue to evaluate the use of lymphocytes as a surrogate marker. When bladder biopsy tissue is not available, urothelial cells will be obtained from a cystoscopic or catheterized bladder lavage.

  Eligibility

Ages Eligible for Study:   21 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • They have been diagnosed with a primary nonmuscle invasive bladder cancer within the previous 12 months.
  • They speak English or a language for which we have a translated consent form
  • They understand and agree to sign informed consent
  • They agree to donate a 30ml blood sample
  • They agree to give us a bladder tissue sample as part of normal clinical procedures (three 3mm cold cup bladder biopsies or urothelial cells by bladder lavage)
  • They agree to complete the study questionnaires
  • They agree to have their pathology information reviewed. This could include biopsy specimens.
  • All subjects must be age 21 or older

Exclusion Criteria:

  • Age less than 21 years
  • History of other cancer diagnosis excluding nonmelanoma skin cancers
  • History of muscle invasive bladder cancer
  • Initial diagnosis more than 12 months from entry date into study
  • History of prior intravenous chemotherapy or radiation therapy
  • Bladder histology other than transitional cell cancer and its variants.
  • Pregnancy
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00582387

Locations
United States, New York
Memorial Sloan-Kettering Cancer Center
New York, New York, United States, 10065
Sponsors and Collaborators
Memorial Sloan-Kettering Cancer Center
Investigators
Principal Investigator: Sherri Donat, MD Memorial Sloan-Kettering Cancer Center
  More Information

Additional Information:
No publications provided

Responsible Party: Memorial Sloan-Kettering Cancer Center
ClinicalTrials.gov Identifier: NCT00582387     History of Changes
Other Study ID Numbers: 04-011
Study First Received: December 19, 2007
Last Updated: July 11, 2013
Health Authority: United States: Institutional Review Board

Additional relevant MeSH terms:
Urinary Bladder Neoplasms
Disease Susceptibility
Recurrence
Genetic Predisposition to Disease
Urologic Neoplasms
Urogenital Neoplasms
Neoplasms by Site
Neoplasms
Urinary Bladder Diseases
Urologic Diseases
Disease Attributes
Pathologic Processes

ClinicalTrials.gov processed this record on April 16, 2014